Raise closed, search for fresh raises on Seedstage

Manhattan Beach, CA

Developing accessible AI-powered full-body scanners for early skin cancer detection.

• Experienced team: Led by a melanoma survivor with three exits and Stanford’s Chief of Dermatology.
• Market need: 98 million Americans require annual skin checks, but capacity only meets half that.
• Proven interest: Gained 2,000 waitlist signups in three weeks with no marketing.
• AI performance: Built on 50,000 datapoints, delivering over 90% diagnostic accuracy.
• Scalable model: Zero-cost scanner deployment with subscription-style recurring revenue.

SkinBit is raising capital to bring AI-powered skin cancer screening to the broader public through an accessible, full-body scanning solution. With dermatologist shortages and increasing rates of skin cancer, the company aims to address a growing gap in preventive care by offering a fast, affordable, and accurate alternative to traditional exams. Their scanner captures a full-body skin map in 60 seconds, allowing AI to identify potential issues with high accuracy. SkinBit plans to deploy these scanners in clinics and third-party locations using a zero-cost partner model, while physicians oversee results until regulatory clearance allows full autonomy.

The company is focused on creating a scalable healthcare solution that provides recurring revenue through medically necessary annual screenings. By starting with dermatologist-assisted assessments and progressing toward fully autonomous AI analysis, SkinBit’s phased regulatory path enables early revenue while building toward broader market access. The company is led by a repeat founder and melanoma survivor, working with Stanford’s Chief of Dermatology and an experienced design team. SkinBit’s goal is to increase early detection, streamline patient care, and bring life-saving diagnostics to millions of underserved individuals in the U.S.

Company Info

SkinBit is developing an AI-driven full-body scanner to improve access and accuracy in early skin cancer detection.

SkinBit is a health technology company developing an AI-powered full-body skin scanner designed to detect early signs of skin cancer. The system captures high-resolution images in 60 seconds and uses machine learning trained on over 50,000 data points to identify lesions with greater than 90% accuracy. Designed to reduce diagnostic errors and address dermatology access gaps, SkinBit tracks changes over time, enabling both patients and doctors to monitor skin health more effectively.

The company plans to deploy scanners in clinics, imaging centers, and flagship locations using a no-cost hardware model, aiming to serve the estimated 98 million Americans in need of annual skin checks. SkinBit’s regulatory strategy allows initial operation with dermatologist oversight while progressing toward full FDA clearance for autonomous AI use. The business model leverages annual screening needs to create recurring revenue, with each scanner projected to generate around $1 million per year.